MediWound Ltd.
MDWD evidence brief
What we can confirm
- BioSniper Score:
- 7.8 / 10
- Market Cap:
- $174.5M
- Lead Asset:
- nexobrid (Approved)
What it means
What to watch
Prepared research question
What matters most for MDWD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDWD
MediWound Ltd. (MDWD) is a publicly traded Israeli biotech company focused on developing and commercializing next-generation enzymatic therapeutics for tissue repair, with two lead products: NexoBrid for burn debridement and EscharEx for chronic wound debridement.
Key risk: Cash burn rate
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 1 pipeline candidate · 4 clinical trials · 1 FDA decision for MediWound Ltd..
MediWound Ltd. (MDWD) is a publicly traded Israeli biotech company focused on developing and commercializing next-generation enzymatic therapeutics for tissue repair, with two lead products: NexoBrid for burn debridement and EscharEx for chronic wound debridement.
- MediWound reported Q2 2026 revenue of $3.1 million, down from $5.7 million in Q2 2025, and reaffirmed full-year 2026 revenue guidance of $24–26 million [news · published 2026-08-13].
- Cash & equivalents were $4.8M as of 2025-12-31 [sec]; the company had $54 million in cash at year-end 2025 [news · published 2026-03-05].
- The EscharEx Phase III VALUE trial in venous leg ulcers is advancing, with an interim assessment and enrollment completion expected by end of Q1 2027 [news · published 2026-08-13].
- An independent DSMB recommended the EscharEx Phase III VALUE study continue without modification, with no safety concerns identified [news · published 2026-09-14].
- A Master Services Agreement was signed with Vericel under its BARDA contract for NexoBrid [news · published 2026-08-13].
What works
- NexoBrid quarterly sales reached a record level in Q2 2026, supporting the company's reaffirmed 2026 revenue guidance of $24–26 million [news · published 2026-08-13].
- The EscharEx Phase III VALUE trial received a positive DSMB recommendation to continue without modification, indicating no early safety concerns [news · published 2026-09-14].
- The company expanded its market opportunity estimate to $1.05 billion in peak annual sales [news · published 2026-08-13].
- Strategic research collaborations have been established with Essity and Convatec [news · published 2025-08-14].
What to weigh
- Q2 2026 revenue of $3.1 million was down from $5.7 million in Q2 2025, reflecting ongoing investment in pipeline programs [news · published 2026-08-13].
- Q1 2026 revenue missed estimates at $1.48 million, though the net loss per share beat forecasts [news · published 2026-05-27].
- Cash & equivalents stood at only $4.8M as of 2025-12-31 [sec], a significant drop from $54 million at year-end 2025 [news · published 2026-03-05], suggesting rapid cash burn.
- The EscharEx Phase III trial is still enrolling and will not complete until at least Q1 2027, meaning no near-term catalyst for that program [news · published 2026-08-13].
From the filings
Quoted directly from source documents.
Q2 2026 revenue and full-year guidance
“Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed”
News · August 13, 2026
DSMB recommendation for EscharEx Phase III
“Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification”
News · September 14, 2026
Cash position at year-end 2025
“$54 million in cash at year-end”
News · March 5, 2026
Interim assessment and enrollment completion timeline for EscharEx
“Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027”
News · August 13, 2026
Catalyst timeline
- 2025-06-01 · Phase 3 Start: EscharEx VALUE trial in venous leg ulcers — A multicenter, randomized, double-blind, placebo-controlled adaptive design study to evaluate efficacy and safety of EscharEx in debridement of venous leg ulcers.
- 2026-08-01 · Phase 2 Start: EscharEx (EX-03) pharmacokinetics and safety study — An open-label, single-treatment, single-arm, multiple-dose Phase 2 study to evaluate pharmacokinetics, safety, and clinical performance of EscharEx in participants with venous leg ulcers.
Risks & what to watch (4)›
Key risks
- Cash burn rate — Cash dropped from $54M (year-end 2025) to $4.8M (2025-12-31 SEC), indicating high burn; runway may be limited without new financing [sec][news]
- Revenue volatility — Q2 2026 revenue ($3.1M) was down 46% from Q2 2025 ($5.7M), showing uneven commercial performance [news]
- Phase III trial execution risk — EscharEx VALUE trial enrollment completion not expected until Q1 2027; any delay or negative interim could hurt pipeline value [news]
- Dependence on NexoBrid — Near-term revenue relies heavily on NexoBrid; any manufacturing or regulatory setback could impact guidance [news]
What to watch
- Interim assessment and enrollment completion of the EscharEx Phase III VALUE trial, expected by end of Q1 2027 [news · published 2026-08-13]
- Regulatory approvals for the expanded NexoBrid manufacturing facility, expected in 2026 [news · published 2026-03-05]
- Full-year 2026 revenue results versus the $24–26 million guidance [news · published 2026-08-13]
- Cash position updates in upcoming quarterly filings, given the rapid decline from $54M to $4.8M [sec][news]
Sources: Catalysts · Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run MediWound Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MediWound Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
6 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
75
Total value held
$84.4M
| Holder | Shares | Value |
|---|---|---|
| investor ab | 872,093 | $14.0M |
| yelin lapidot holdings management ltd. | 762,817 | $12.3M |
| rosalind advisors, inc. | 749,054 | $12.1M |
| blackrock, inc. | 445,834 | $7.2M |
| meitav investment house ltd | 371,868 | $6.0M |
| sphera funds management ltd. | 273,192 | $4.4M |
| silverberg bernstein capital management llc | 200,005 | $3.2M |
| point72 asset management, l.p. | 175,479 | $2.8M |
| ubs group ag | 159,791 | $2.6M |
| state street corp | 143,770 | $2.3M |
Showing top 10 of 75 institutional holders of MediWound Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 13.9%
- Days to cover
- 19.2
- Shares short
- 1,558,289
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDWD short interestFrequently asked questions
What is the AI investment thesis for MediWound Ltd.?
MediWound Ltd. (MDWD) is a publicly traded Israeli biotech company focused on developing and commercializing next-generation enzymatic therapeutics for tissue repair, with two lead products: NexoBrid for burn debridement and EscharEx for chronic wound debridement.
What is MediWound Ltd.'s lead drug candidate?
MediWound Ltd.'s most advanced tracked candidate is nexobrid (Approved).
Who is the CEO of MediWound Ltd.?
Mr. Ofer Gonen B.Sc. is the chief executive officer of MediWound Ltd. (MDWD).
Where is MediWound Ltd. headquartered?
MediWound Ltd. (MDWD) is headquartered in Yavne, Israel.
What therapeutic areas does MediWound Ltd. focus on?
MediWound Ltd. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.